NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 10 November 2022, 09:30am

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Dr Hatim Abdulhussein Present for all items
4. Maria Brezitski Present for all items
5. Professor Iolo Doull Present for all items
6. Professor Francis Drobniewski Present for all items
7. Dr Mark Glover Present for all items
8. Dr Bushra Hasnie Present for all items
9. Dr Veline L’Esperance Present for all items
10. Professor Nicholas Latimer Present for all items
11. Professor David McAllister Present for all items
12. Dr Rhiannon Owen Present for all items
13. Anna Pracz Present for all items
14. Gabriel Rogers  Present for all items
15. Mary Weatherstone Present for items 1 to 4.2.1
16. Professor Nicky Welton Present for all items
17. Nigel Westwood Present for all items
18. Peter Wheatley-Price Present for all items
19. Tony Wootton Present for all items

NICE staff (key players) present

Henry Edwards, Associate Director Present for all items

Jeremy Powell, Project Manager Present for all items

Lorna Dunning, Heath Technology Assessment Adviser Present for all items

Raphael Egbu, Heath Technology Assessment Analyst Present for all items

Sarah Bromley, Senior Medical Editor Present for all items

Philip Williams, Business Analyst, RIA Present for all items

Laura Marsden, Public Involvement Adviser, PIP Present for all items

Laura Kelly, Assistant Project Manager, COT Present for all items

Emma Gordon, Coordinator, MIP Items 1 to 4.1.3

Rumana Zaman, Administrator, TA Present for all items

NICE staff (observers) present

Ian Watson, Senior Technical Adviser - Methods and Processes Present for all items

External assessment group representatives present

Nigel Armstrong, Kleijnen Systematic Reviews (KSR) Items 1 to 4.1.3

Willem Witlox, Kleijnen Systematic Reviews (KSR) Items 1 to 4.1.3

Clinical, Patient & NHS England experts present

Jane Ashford, Patient Expert, nominated by Bowel Cancer UK, items 1 to 4.1.3

Professor Peter Clark, Cancer Drugs Fund Lead, NHS England, present for all items

Dr Harpreet Wasan Singh, Clinical Expert and Consultant in Oncology, nominated by Bayer PLC LTD, items 1 to 4.1.3

Dr Richard Wilson, Clinical Expert and Professor of Gastrointestinal Oncology, nominated by the National Cancer Research Institute (NCRI) Items 1 to 4.1.3

## Minutes

### Introduction to the meeting

* 1. The vice chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Dr Toby Smith and Dr Stuart Williams.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 15 September and Thursday 13 October 2022.
1. **Appraisal of Appraisal of regorafenib for previously treated metastatic colorectal cancer [ID4002]**
	1. Part 1 – Open session
		1. The Vice Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from
		2. The Vice Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Harpreet Wasan Singh declared a direct financial interest as he received renumeration for advisory boards, speaker fees and research in relation to regorafenib from Bayer. Dr Singh also declared an indirect financial interest, due to having carried out similar work for Servier in relation to Trifluridine-tipiracil hydrochloride. It was agreed that his declaration would not prevent Dr Singh from providing expert advice to the committee.
* Dr Richard Wilson declared an direct financial interest he has received research funding for an aspirin clinical trial from Bayer. Dr Wilson also declared an indirect financial interest as he was also involved in advisory boards and educational work with Servier, for Trifluridine-tipiracil hydrochloride before its launch in the UK, but not in relation to competition against regorafenib. It was agreed that his declaration would not prevent DR Wilson from providing expert advice to the committee.
	+ 1. The Vice Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Mark Glover (Clinical) Anna Pracz (Cost) and Tony Wootton (Lay).
	1. Part 2 - Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10924>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Wednesday 14 December and will start promptly at 09:30am.